Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland (HepCOP)

This study has been completed.
Sponsor:
Collaborator:
University of Zurich
Information provided by:
Seidenberg, Arztpraxis A., M.D.
ClinicalTrials.gov Identifier:
NCT00473993
First received: May 15, 2007
Last updated: February 13, 2009
Last verified: May 2007
  Purpose

Hepatitis C viral infection is common among opioid addicts in Zurich, Switzerland. The majority undergoes a maintenance treatment with methadone, heroin or buprenorphine. While stabilized by an opioid maintenance treatment (OMT)chronic hepatitis C can be treated with pegylated interferon plus ribavirin. As not sufficiently known, the results are comparable to the results of the treatment of nonaddicts.

Our crossectional study investigates how many patients undergoing OMT are adequately investigated concerning hepatitis C. If not, why are they not adequately investigated and treated? Representative data are collected in the local clinics and medical practices involved in OMT in the Kanton of Zurich. The patients files are revised and the involved doctors are asked through a structured interview.


Condition
Hepatitis C, Chronic
Substance Abuse Treatment Centers
Opioid-Related Disorders

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Hepatitis C Bei Opioidabhängigen in Der Praxis, Eine Querschnittsuntersuchung

Resource links provided by NLM:


Further study details as provided by Seidenberg, Arztpraxis A., M.D.:

Study Start Date: July 2007
Study Completion Date: December 2007
Detailed Description:

www.seidenberg.ch/hepcop.pdf

  Eligibility

Genders Eligible for Study:   Both
Study Population

Patients in opioid maintenance treatment in the kanton of Zurich, Switzerland

Criteria

Inclusion Criteria:

  • Medical practices and clinics involved in opioid maintenance treatment in the Kanton of Zurich, Switzerland
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00473993

Sponsors and Collaborators
Seidenberg, Arztpraxis A., M.D.
University of Zurich
Investigators
Study Director: André Seidenberg, Dr.med. research fellow EHAM, University of Zurich
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00473993     History of Changes
Other Study ID Numbers: HepCOP Zurich
Study First Received: May 15, 2007
Last Updated: February 13, 2009
Health Authority: Switzerland: Ethikkommission

Keywords provided by Seidenberg, Arztpraxis A., M.D.:
Hepatitis C
Opioid Maintenance Treatment
Methadone
Buprenorphine
Heroin
Interferon, pegylated

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Opioid-Related Disorders
Hepatitis C, Chronic
Substance-Related Disorders
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Chemically-Induced Disorders
Mental Disorders
Hepatitis, Chronic
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 27, 2014